title: Recent advances in anti-angiogenic therapy of cancer.
abstract: Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic treatment is a highly promising therapeutic approach. Thus, for over last couple of decades, there has been a robust activity aimed towards the discovery of angiogenesis inhibitors. More than forty anti-angiogenic drugs are being tested in clinical trials all over the world. This review discusses agents that have approved by the FDA and are currently in use for treating patients either as single-agents or in combination with other chemotherapeutic agents.
authors.affiliation: Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA. rsamant@usouthal.edu
authors.forename: Rajeev S
authors.initials: RS
authors.lastname: Samant
authors.forename: Lalita A
authors.initials: LA
authors.lastname: Shevde
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal